The development of conditionally replicative adenoviruses for cancer therapy

Clinical Cancer Research

Volumn 6, Issue 9, 2000, Pages 3395-3399

  Curiel, D T ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS; CANCER THERAPY; CELL KILLING; DRUG DESIGN; HUMAN; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; VIRUS CELL INTERACTION; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRIDAE INFECTIONS; ANIMALS; HUMANS; NEOPLASMS; VIRUS REPLICATION;

EID: 0033817601     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (45)

1. Viruses in the treatment of cancer
2. Treatment of human cancer with mumps virus
3. Clinical studies of viruses as antineoplastic agents, with particular reference to Egypt 101 virus
4. Studies on the use of viruses in the treatment of carcinoma of the cervix
5. Gene therapy for gliomas: Molecular targets, adenoviral vectors, and oncolytic adenoviruses
6. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
7. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
8. Role of α(v) integrins in adenovirus cell entry and gene delivery
9. Targeted gene delivery by tropism-modified adenoviral vectors
10. Control of cellular and viral transcription during adenovirus infection
11. Mechanism of DNA replication in eukaryotic cells: Cellular host factors stimulating adenovirus DNA replication
12. Advances in adenoviral vectors: From genetic engineering to their biology
13. p53 molecule as a prognostic marker in human malignancies
14. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
15. ONYX-015: Clinical data are encouraging
16. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p52 status
17. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection
18. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma
19. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: The importance of the adenoviral E1b-55kD gene
20. Replication of ONYX-015, a potential anticancer adenovirus is independent of p53 status in tumor cells
21. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
22. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins
23. Characteristics of a human cell line transformed by DNA from human adenovirus type 5
24. The addition of adenovirus type 5 region E3 enables Calydon virus 787 to eliminate distant prostate tumor xenografts
25. In vivo antitumor effect of retrovirus-mediated gene transfer of the adenovirus ela gene
26. Complementary adenoviral vectors for oncolysis
27. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
28. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase
29. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer
30. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
31. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism
32. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches
33. Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy
34. E2F1 and E1A(12S) have a homologous activation domain regulated by RB and CBP
35. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination
36. Oncolytic virus therapy of multiple tumors in a brain requires suppression of innate and elicited antiviral responses
37. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide
38. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig
39. Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors
40. Cellular immunity delimits adenoviral gene therapy strategies for the treatment of neoplastic diseases
41. Generation of adenovirus vectors devoid of all viral genes by recombination between inverted repeats
42. Insulation of a conditionally expressed transgene in an adenoviral vector
43. Applications of DNA shuffling to pharmaceuticals and vaccines
44. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas
45. Adenovirus-mediated cytotoxicity of chronic lymphocytic leukemia cells